Cardinal Health generated $36.7 billion in sales and $656 million in profits during its fiscal fourth quarter, which ended June 30. "In fiscal 2020, we delivered on our commitments, grew operating earnings and exceeded our EPS guidance, despite the unprecedented global environment," said Cardinal Health CEO Mike Kaufmann.

AstraZeneca and China's BioKangtai have entered into a licensing deal for AZ's COVID-19 vaccine candidate AZD1222, developed by the UK's University of Oxford, to supply the shots to China. The companies, which did not disclose the deal's financial terms, will also consider vaccine production for other countries, with AZ granting BioKangtai exclusive clinical development, manufacturing, and marketing rights in China.

Researchers from the University of Exeter in the UK have created a highly sensitive antibody test that can detect COVID-19 and four other common flu strains, delivering results within seven minutes.

The FDA has updated a technical specifications document that offers detailed information on electronic submission of clinical trial data for companies seeking biologics license applications, new drug applications and supplemental filings. The updated document includes "current FDA specifications, recommendations, and general considerations" related to the preparation and electronic submission of clinical study-level information, subject-level data line listings by clinical site, and summary-level clinical site datasets that will be used to plan for bioresearch monitoring inspections.

Meridian Bioscience generated $84.8 million in revenues during its fiscal third quarter, up 75% from the same period a year earlier, due to demand for COVID-19 products.

A Series B financing round has raised $12.2 million for Tangen Biosciences. The funds will be used to accelerate development of its panel test that can simultaneously detect SARS-CoV-2, influenza A/B and respiratory syncytial virus, as well as boost manufacturing capacity of its point-of-care SARS-CoV-2 test.

Bausch + Lomb will be spun off into a standalone business by its parent company Bausch Health Companies. "We've looked at the value of our pure health companies like Alcon and Cooper and believe that Bausch + Lomb would compare very favorably," said Bausch Health CEO Joseph Papa.

Autobio Diagnostics' emergency use authorization for its Anti-SARS-CoV-2 Rapid Tests for IgM and IgG antibodies has been revoked by the FDA due to accuracy concerns.

The FDA has approved Guardant Health's Guardant360 Dx to be used to profile tumor mutations in patients with any solid malignant tumor.

Vive Crop Protection and Marrone Bio Innovations will introduce a new line of products in the US enhanced using biological and conventional chemistry through Vive's novel Allosperse Delivery System. "The collaboration with MBI allows us to bring growers the best of three approaches to crop protection: chemistry, biologicals and nanotechnology," said Dan Bihlmeyer, Vive Crop Protection's vice president of sales and marketing.